Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tetrandrine for Hospitalized Adults With COVID-19
NCT05697029Phase 4Withdrawn
- Sponsor
- Peking University Third Hospital
- Start
- Dec 2023
- Primary completion
- Dec 2025
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of tetrandrine in coronavirus disease 2019 (COVID-19), sponsored by Peking University Third Hospital. Planned start Dec 2023; status: withdrawn.
02
Drugs
tetrandrine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05697029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05697029.